Clinical and economic impact of 2nd line initiation of empagliflozin after metformin, as compared to 2nd line initiation of sulfonylurea after metformin in patients with type 2 diabetes and cardiovascular disease

27/10/2021
27/10/2026
EU PAS number:
EUPAS43815
Study
Cancelled
Documents
Study protocol
Initial protocol
English (622.15 KB - PDF) View document
Study results
No information provided.
Study report
No information provided.
ENCePP Seal
No information provided.